8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin's antidepressant profile: Synthesis, biological evaluation and docking studies
Autor
Matos, Maria J.
Novo, Paula
Mayán, Lucía
Torres, Iria
Uriarte, Eugenio
Yáñez, Matilde
Fontenla, José Ángel
Ortuso, Francesco
Alcaro, Stefano
Procopio, Francesca
Rodríguez-Franco, María Isabel
Val, Cristina
Loza, María I.
Brea, José
Borges, Fernanda
Viña, Dolores
Resumen
Psychiatric and neurological disorders affect millions of people worldwide. Currently available treatments may help to improve symptoms, but they cannot cure the diseases. Therefore, there is an urgent need for potent and safe therapeutic solutions. 8-Amide and 8-carbamatecoumarins were synthetized and evaluated as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors. Comparison between both scaffolds has been established, and we hypothesized that the introduction of different substituents can modulate hMAO activity and selectivity. N-(7-Hydroxy-4-methylcoumarin-8-yl)-4-methylbenzamide (9) and ethyl N-(7-hydroxy-4-methylcoumarin-8-yl)carbamate (20) proved to be the most active and selective hMAO-A inhibitors (IC50 = 15.0 nM and IC50 = 22.0 nM, respectively), being compound 9 an irreversible hMAO-A inhibitor twenty-four times more active in vitro than moclobemide, a drug used in the treatment of depression and anxiety. Based on PAMPA assay results, both compounds proved to be good candidates to cross the blood-brain barrier. In addition, these compounds showed non-significant cytotoxicity on neuronal viability assays. Also, the best compound proved to have a t1/2 of 6.84 min, an intrinsic clearance of 195.63 μL min−1 mg−1 protein, and to be chemically stable at pH 3.0, 7.4 and 10.0. Docking studies were performed to better understand the binding affinities and selectivity profiles for both hMAO isoforms. Finally, theoretical drug-like properties calculations corroborate the potential of both scaffolds on the search for new therapeutic solutions for psychiatric disorders as depression. © 2023 The Authors
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
4-Oxoquinolines and monoamine oxidase: When tautomerism matters (2021)
Mesiti, Francesco; Maruca, Annalisa; Silva, Vera L.M.; Rocca, Roberta; Fernandes, Carlos; Remião, Fernando; Uriarte, Eugenio; Alcaro, Stefano; Gaspar, Alexandra; Borges, Fernanda (Elsevier Masson s.r.l., 2021-03-05)4-Oxoquinoline derivatives have been often used in drug discovery programs due to their pharmacological properties. Inspired on chromone and 4-oxoquinoline chemical structure similarity, a small series of quinoline-based ... -
Article
Curcumin–coumarin hybrid analogues as multitarget agents in neurodegenerative disorders (2021)
Quezada, Elías; Rodríguez-Enríquez, Fernanda; De Los Reyes Laguna, Maria; Cutrín, Elena; Otero, Francisco; Uriarte, Eugenio; Viña, Dolores (MDPI AG, 2021-08-01)Neurodegenerative diseases have a complex nature which highlights the need for multitarget ligands to address the complementary pathways involved in these diseases. Over the last decade, many innovative curcumin-based ... -
Article
Coumarin-Resveratrol-Inspired Hybrids as Monoamine Oxidase B Inhibitors: 3-Phenylcoumarin versus trans-6-Styrylcoumarin (2022)
Mellado, Marco; Gonzalez, Cesar; Mella-Raipán, Jaime A.; Aguilar, Luis Felipe; Celik, Ismail; Borges, Fernanda; Uriarte, Eugenio; Delogu, G. L.; Viña, Dolores; Matos, Maria J. (MDPI, 2022-02-01)Monoamine oxidases (MAOs) are attractive targets in drug design. The inhibition of one of the isoforms (A or B) is responsible for modulating the levels of different neurotransmitters in the central nervous system, as well ...